GlobeNewswire: Oklahoma Medical Research Foundation Contains the last 10 of 8 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T15:56:23ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2018/10/29/1638462/0/en/Oblato-acquires-all-rights-to-glioblastoma-drug-from-OMRF.html?f=22&fvtc=4&fvtv=36223Oblato acquires all rights to glioblastoma drug from OMRF2018-10-29T15:21:05Z<![CDATA[OKLAHOMA CITY, Oct. 29, 2018 (GLOBE NEWSWIRE) -- Oblato, Inc., has acquired all rights from the Oklahoma Medical Research Foundation to OKN-007, an investigational drug for the treatment of glioblastoma, a deadly form of brain cancer.]]>https://www.globenewswire.com/news-release/2018/02/13/1340168/0/en/Novel-treatment-of-hemophilia-OMRF-enters-license-agreement-with-Shanghai-RAAS-Blood-Products.html?f=22&fvtc=4&fvtv=36223Novel treatment of hemophilia: OMRF enters license agreement with Shanghai RAAS Blood Products2018-02-13T20:02:03Z<![CDATA[OKLAHOMA CITY, Feb. 13, 2018 (GLOBE NEWSWIRE) -- The Oklahoma Medical Research Foundation has entered a license agreement with Shanghai RAAS Blood Products Co., Ltd. Under the agreement, Shanghai RAAS has the exclusive rights to develop and market novel drugs to treat hemophilia and traumatic bleeding based on technologies developed at OMRF.]]>https://www.globenewswire.com/news-release/2017/07/24/1056198/0/en/OMRF-collaborates-with-GSK-to-develop-novel-treatments-for-severe-inflammatory-diseases.html?f=22&fvtc=4&fvtv=36223OMRF collaborates with GSK to develop novel treatments for severe inflammatory diseases2017-07-24T15:00:00Z<![CDATA[OKLAHOMA CITY, July 24, 2017 (GLOBE NEWSWIRE) -- The Oklahoma Medical Research Foundation (OMRF) has signed a collaboration agreement with GSK, one of the world’s leading healthcare companies, for the discovery, development and commercialization of novel therapies to prevent organ damage and death caused by conditions such as acute pancreatitis, lung injury and trauma.]]>https://www.globenewswire.com/news-release/2016/10/26/959707/0/en/Eisai-Oklahoma-Medical-Research-Foundation-enter-autoimmune-disease-research-collaboration.html?f=22&fvtc=4&fvtv=36223Eisai, Oklahoma Medical Research Foundation enter autoimmune disease research collaboration2016-10-26T12:00:00Z<![CDATA[WOODCLIFF LAKE, NJ and OKLAHOMA CITY, OK--(Marketwired - October 26, 2016) - Eisai Inc. and the Oklahoma Medical Research Foundation (OMRF) have formed a research collaboration to study the autoimmune disease lupus.]]>https://www.globenewswire.com/news-release/2016/02/15/959706/0/en/GtreeBNT-Acquires-New-Drug-for-the-Treatment-of-Glioblastomas.html?f=22&fvtc=4&fvtv=36223GtreeBNT Acquires New Drug for the Treatment of Glioblastomas2016-02-15T18:00:00Z<![CDATA[PRINCETON, NJ, and OKLAHOMA CITY, OK--(Marketwired - February 15, 2016) - GtreeBNT Co., Ltd., has entered into an agreement with the Oklahoma Medical Research Foundation (OMRF) to acquire the rights to OKN-007, a new investigational drug for the treatment of glioblastoma, a deadly form of brain cancer.]]>https://www.globenewswire.com/news-release/2015/10/22/959705/0/en/OMRF-Biogen-Enter-Autoimmune-Disease-Collaboration.html?f=22&fvtc=4&fvtv=36223OMRF, Biogen Enter Autoimmune Disease Collaboration2015-10-22T15:55:16Z<![CDATA[OKLAHOMA CITY, OK--(Marketwired - October 22, 2015) - The Oklahoma Medical Research Foundation and Biogen have formed a research collaboration.]]>https://www.globenewswire.com/news-release/2015/09/30/959704/0/en/OMRF-and-Progentec-Collaborate-to-Commercialize-New-Autoimmune-Diagnostics.html?f=22&fvtc=4&fvtv=36223OMRF and Progentec Collaborate to Commercialize New Autoimmune Diagnostics2015-09-30T20:06:55Z<![CDATA[OKLAHOMA CITY, OK--(Marketwired - September 30, 2015) - Progentec Diagnostics, Inc. and the Oklahoma Medical Research Foundation have entered into a new collaboration to create tools designed to improve the treatment of autoimmune diseases. The initial project will focus on developing a diagnostic test to identify patients at increased risk of disease flares in lupus.]]>https://www.globenewswire.com/news-release/2015/04/09/959703/0/en/VCs-Biotech-Execs-Converge-on-Oklahoma-City.html?f=22&fvtc=4&fvtv=36223VCs, Biotech Execs Converge on Oklahoma City 2015-04-09T20:56:53Z<![CDATA[OKLAHOMA CITY, OK--(Marketwired - Apr 9, 2015) - This week, more than 30 leading venture capitalists and biotechnology industry executives spent the day in Oklahoma City. They were there to attend OMRF BioVenture Forum 2015, hosted by the Oklahoma Medical Research Foundation.]]>